12 completed. 12 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 12 | Completed 12 |
Follow Fungal Infection: new trials by email Literature Review of Fungal Infection trials Research Report on Fungal Infection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation Rezafungin for Injection, Posaconazole, Fluconazole - Candidemia, Mycoses | Phase 3 | Completed | Mundipharma Research Limited | 602 | 2020-05-11 | 2026-04-13 |
| Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis Rezafungin for Injection, Caspofungin, Fluconazole - Candidemia, Mycoses | Phase 3 | Completed | Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 199 | 2018-10-07 | 2023-01-06 |
| Caspofungin Acetate, Fluconazole, or Voriconazole in Preventing Fungal Infections in Patients Following Donor Stem Cell Transplant Caspofungin Acetate, Fluconazole, Laboratory Biomarker Analysis - Fungal Infection, Hematopoietic and Lymphoid Cell Neoplasm | Phase 3 | Completed | Children's Oncology Group | 292 | 2013-03-21 | 2024-10-16 |
| Empirical Versus Preemptive Antifungal Therapy caspofungin acetate - Fungal Infection, Leukemia | Phase 3 | Completed | European Organisation for Research and Treatment of Cancer - EORTC | 556 | 2012-03-01 | 2023-12-11 |
| Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation levofloxacin - Acute Leukemias of Ambiguous Lineage, Bacterial Infection | Phase 3 | Completed | Children's Oncology Group | 624 | 2011-09-01 | 2020-12-07 |
| Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia Caspofungin Acetate, Fluconazole, Laboratory Biomarker Analysis - Acute Myeloid Leukemia, Adult Acute Monoblastic Leukemia | Phase 3 | Completed | Children's Oncology Group | 517 | 2011-04-04 | 2021-03-30 |
| Beta Glucan Assay in Patients Receiving Voriconazole Prophylaxis Voriconazole - Leukemia, Fungal Infection | Phase 3 | Completed | M.D. Anderson Cancer Center | 23 | 2009-05-01 | 2012-08-07 |
| Posaconazole Treatment of Invasive Fungal Infection (IFI) (P05551) Posaconazole - Fungal Infection | Phase 3 | Completed | Merck Sharp & Dohme LLC | 63 | 2008-11-01 | 2017-04-07 |
| A Clinical Study of MK0991 (Caspofungin) in Japanese Patients With Deep-seated Candida or Aspergillus Infections (0991-062)(COMPLETED) caspofungin acetate, Comparator: Micafungin sodium - Fungal Infection | Phase 3 | Completed | Merck Sharp & Dohme LLC | 121 | 2008-08-01 | 2017-03-23 |
| A Study of Caspofungin Acetate (MK0991) for the Treatment of Esophageal Candidiasis or Invasive Candidiasis in Chinese Adults (MK-0991-066) caspofungin acetate - Fungal Infection | Phase 3 | Completed | Merck Sharp & Dohme LLC | 63 | 2008-01-01 | 2017-03-24 |
| Evaluate the Safety and Efficacy of Caspofungin Acetate as Empirical Therapy in Chinese Adults With Persistent Fever and Neutropenia (0991-055) MK0991, caspofungin acetate / Duration of Treatment: - Fungal Infection | Phase 3 | Completed | Merck Sharp & Dohme LLC | 131 | 2006-03-01 | 2015-12-17 |
| A 28 - 90 Days Study to Evaluate the Safety, Tolerability, and Efficacy of Caspofungin Injection as Empirical Therapy in Indian Adults With Persistent Fever and Neutropenia (0991-053)(COMPLETED) caspofungin acetate - Fungal Infection | Phase 3 | Completed | Merck Sharp & Dohme LLC | 50 | 2005-06-01 | 2017-02-23 |
Mycoses (12) · Invasive Fungal Infections (4) · Leukemia (3) · Candidemia (2) · Candidiasis (2) · Candidiasis, Invasive (2) · Fungemia (2) · Hematologic Neoplasms (2) · Leukemia, Myeloid, Acute (2) · Neutropenia (2) · Pathologic Processes (2) · Sepsis (2) · Systemic Inflammatory Response Syndrome (2) · Bacterial Infections (1) · Congenital Abnormalities (1)
Bacterial Infections and Mycoses (12) · Infections (11) · Hematologic Diseases (5) · Hemic and Lymphatic Diseases (5) · Neoplasms (5) · Neoplasms by Histologic Type (4) · Pathological Conditions, Signs and Symptoms (3) · Agranulocytosis (2) · Cytopenia (2) · Leukemia, Myeloid (2) · Leukocyte Disorders (2) · Leukopenia (2) · Neoplasms by Site (2) · Shock (2) · Bone Marrow Diseases (1)
Caspofungin (8) · Fluconazole (4) · Injections (2) · Rezafungin (2) · Voriconazole (2) · posaconazole (2) · Duration of Therapy (1) · Levofloxacin (1) · Trimethoprim, Sulfamethoxazole Drug Combination (1)
Merck Sharp & Dohme LLC (5) · Children's Oncology Group (3) · Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · M.D. Anderson Cancer Center (1) · Mundipharma Research Limited (1)
United States (6) · Canada (4) · Belgium (3) · France (3) · Germany (3) · Italy (2) · Spain (2) · Argentina (1) · Australia (1) · Bulgaria (1) · China (1) · Colombia (1) · Czechia (1) · Greece (1) · Israel (1)
Christopher C Dvorak (1) · Jorge Cortes, MD (1) · Laura Cox, PhD (1) · Sarah Alexander, MD (1) · Taylor Sandison, MD, MPH (1) · Theoklis E Zaoutis (1)
PMID 33438477, PMID 22324990, PMID 23052987, PMID 31688884, PMID 33136159, PMID 35906831, PMID 36442484, PMID 37773627, PMID 38008099, PMID 38502709, PMID 38985561, PMID 39259571, PMID 39468640, PMID 39529079, PMID 41194465, PMID 41940006
U10CA095861 (3), UG1CA189955 (2), 2017 (1)